Alamar Biosciences, Inc. Common Stock (ALMR)vsEdwards Lifesciences Corp (EW)
ALMR
Alamar Biosciences, Inc. Common Stock
$25.04
+2.29%
HEALTHCARE · Cap: $1.67B
EW
Edwards Lifesciences Corp
$81.22
-1.29%
HEALTHCARE · Cap: $46.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 8394% more annual revenue ($6.30B vs $74.21M). EW leads profitability with a 17.4% profit margin vs -40.2%. EW earns a higher WallStSmart Score of 61/100 (C+).
ALMR
Avoid16
out of 100
Grade: F
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMR.
Margin of Safety
+70.0%
Fair Value
$264.83
Current Price
$81.22
$183.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 31.2%
16.7% revenue growth
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -33.6% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMR
ALMR has a balanced fundamental profile.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ALMR
The primary concerns for ALMR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 43.9x leaves little room for execution misses.
Key Dynamics to Monitor
ALMR profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
EW is growing revenue faster at 16.7% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (61/100 vs 16/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?